Last updated: February 19, 2026

Repaglinide and metformin hydrochloride combination products represent a significant segment within the type 2 diabetes mellitus (T2DM) market. This fixed-dose combination (FDC) therapy offers dual mechanisms of action to improve glycemic control, targeting both postprandial and fasting hyperglycemia. The market is characterized by patent expirations, the proliferation of generic alternatives, and ongoing competition from newer therapeutic classes. Understanding the market dynamics and financial trajectory of these drugs requires an analysis of patent landscapes, generic penetration, pricing strategies, and the evolving treatment paradigms for T2DM.

What is the Current Market Size and Projected Growth for Repaglinide and Metformin Hydrochloride?

The global market for repaglinide and metformin hydrochloride, primarily as generic FDCs, is substantial but subject to price erosion due to intense competition. Precise market size figures for this specific FDC are often embedded within broader oral antidiabetic drug (OAD) market reports, making granular extraction challenging. However, estimates based on the combined market share of individual components and FDC penetration suggest a market value in the hundreds of millions of U.S. dollars annually.

Market Size (Estimated):

Global Market Value: $300 million - $500 million USD (as of 2023, estimated).
Regional Dominance: Asia-Pacific, particularly India and China, accounts for a significant portion of the volume due to lower pricing and higher prevalence of T2DM. North America and Europe represent substantial value markets despite lower volume due to higher pricing.

Projected Growth:

Compound Annual Growth Rate (CAGR): -2% to 1% (projected for 2024-2029). The market is expected to experience modest decline or flat growth. This is primarily driven by:
- Generic Competition: Widespread availability of generics has led to significant price reductions.
- Therapeutic Advancements: Newer drug classes such as GLP-1 receptor agonists and SGLT2 inhibitors are increasingly favored for their cardiovascular and renal benefits, diverting market share.
- Patent Expirations: The original patents for repaglinide and metformin have long expired, allowing for unfettered generic manufacturing.

What is the Patent Landscape for Repaglinide and Metformin Hydrochloride?

The patent landscape for repaglinide and metformin hydrochloride is characterized by expired foundational patents, with remaining intellectual property focusing on formulation improvements, manufacturing processes, and specific combination dosages.

Key Patents and Expirations:

Repaglinide:
- Original Composition of Matter Patent: Expired in the early to mid-2000s in major markets.
- Formulation and Manufacturing Patents: Various patents related to specific tablet formulations (e.g., immediate-release, orally disintegrating tablets) and synthesis routes have expired or are nearing expiration. For instance, patents covering specific crystalline forms or manufacturing processes might have been filed in the late 1990s or early 2000s, typically lasting 20 years from filing.
Metformin Hydrochloride:
- Original Compound Patent: Expired in the late 1970s globally.
- Extended-Release Formulations: Significant patent activity surrounds extended-release (ER) formulations of metformin, which aim to reduce gastrointestinal side effects and improve patient compliance. These patents, often filed in the 1990s and early 2000s, have largely expired or are in their final years of protection.

Fixed-Dose Combination (FDC) Patents:

Patents covering the specific combination of repaglinide and metformin hydrochloride, and their respective dosages within a single tablet, would have been filed after the individual components were established.
These FDC patents are also largely expired, allowing generic manufacturers to produce identical or bioequivalent formulations. For example, a patent filed around 2005 for a specific FDC formulation would likely expire around 2025.
Key Manufacturers' FDC Products:
- PrandiMet (Repaglinide and Metformin HCl): Originally marketed by Novo Nordisk. Its patent exclusivity would have ended in the late 2000s/early 2010s, paving the way for generics.

Remaining IP Focus:

Manufacturing Process Patents: Newer patents may focus on more efficient, cost-effective, or environmentally friendly synthesis methods for either drug or their FDC.
Polymorph and Crystal Form Patents: Protection for specific, stable, or bioavailable crystalline forms of repaglinide or metformin hydrochloride within the FDC.
Dosage Form Innovations: Patents for novel delivery systems or improved formulations that offer enhanced patient compliance or reduced side effects, though this is less common for older drug classes.

Who are the Key Market Players and Competitors?

The market for repaglinide and metformin hydrochloride FDCs is dominated by generic manufacturers, with originator companies having largely exited or transitioned their focus to newer therapies.

Major Generic Manufacturers:

India: Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Lupin Limited, Cipla. These companies are significant suppliers to global markets, particularly in emerging economies.
China: Hengrui Medicine, WuXi AppTec (contract manufacturing), and numerous smaller domestic producers.
United States/Europe: Teva Pharmaceutical Industries, Viatris (formerly Mylan and Pfizer's Upjohn), Aurobindo Pharma, Accord Healthcare. These companies primarily serve North American and European markets.

Originator Companies (Historical/Limited Presence):

Novo Nordisk: Formerly marketed the branded product PrandiMet. Their current presence is minimal, focusing on newer T2DM agents.
Merck & Co.: Marketed repaglinide under the brand name Prandin. Similar to Novo Nordisk, their focus has shifted.

Competition Landscape:

Intense Generic Competition: The market is highly fragmented with numerous generic players, leading to continuous price pressure and thin profit margins.
Therapeutic Alternatives: The primary competitive threat comes from newer classes of antidiabetic drugs:
- DPP-4 Inhibitors (e.g., Sitagliptin, Saxagliptin): Offer glycemic control with a low risk of hypoglycemia.
- SGLT2 Inhibitors (e.g., Empagliflozin, Dapagliflozin): Provide significant cardiovascular and renal benefits, becoming first-line or early-add-on therapies in many guidelines.
- GLP-1 Receptor Agonists (e.g., Liraglutide, Semaglutide): Demonstrate robust glycemic control, weight loss, and cardiovascular benefits.
- Insulin Therapies: Remain a cornerstone for advanced T2DM management.
Other Oral Combinations: FDCs combining metformin with other OADs like sulfonylureas, DPP-4 inhibitors, or SGLT2 inhibitors offer alternative treatment pathways.

What are the Pricing and Reimbursement Dynamics?

Pricing and reimbursement for repaglinide and metformin hydrochloride FDCs are largely dictated by generic market dynamics and health economics policies.

Pricing Trends:

Significant Price Erosion: Since the loss of patent exclusivity for both active pharmaceutical ingredients (APIs) and FDC formulations, prices have fallen dramatically.
Volume-Based Pricing: Manufacturers offer tiered pricing based on purchase volume, especially for tenders and large healthcare systems.
Geographic Variation: Prices vary significantly by region, with North America and Western Europe having higher prices than emerging markets where affordability is a primary driver. For instance, a month's supply might cost $5-$15 USD in the U.S. for a generic FDC, while it could be less than $1-$2 USD in parts of Asia.
API Cost Fluctuations: The cost of sourcing raw materials and APIs, particularly from China and India, can influence final product pricing.

Reimbursement Status:

Widely Covered as Generics: In most developed markets, generic repaglinide and metformin hydrochloride FDCs are covered by public and private health insurance plans as cost-effective treatment options for T2DM.
Formulary Placement: They are typically placed on formularies, often with prior authorization requirements or as a second-line/third-line option after metformin monotherapy or other classes.
Guideline Influence: Treatment guidelines from organizations like the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) increasingly recommend newer agents with proven cardiovascular and renal benefits over older classes for patients with specific comorbidities. This can lead to reduced reimbursement or less favorable formulary placement for older FDCs in certain patient populations.
Emerging Markets: Reimbursement structures are often less formalized, with out-of-pocket expenditures being more common. Availability is driven by affordability and prescriber preference.

What are the Regulatory Considerations and Market Access Challenges?

Regulatory hurdles and market access challenges for repaglinide and metformin hydrochloride FDCs are primarily associated with generic approvals, quality standards, and the evolving regulatory landscape for T2DM treatments.

Regulatory Approvals:

Generic Drug Applications: Manufacturers must obtain Abbreviated New Drug Applications (ANDAs) in the U.S. or Marketing Authorisation Applications (MAAs) in Europe, demonstrating bioequivalence to the reference listed drug (RLD) and adherence to Good Manufacturing Practices (GMP).
Quality and Safety Standards: Regulatory bodies like the FDA and EMA conduct rigorous inspections of manufacturing facilities and require comprehensive quality control data to ensure product safety and efficacy.
Global Harmonization: Manufacturers often seek approvals in multiple regions, navigating differing regulatory requirements and timelines.

Market Access Challenges:

Intensifying Competition: The sheer number of generic manufacturers creates a highly competitive environment, making it difficult to gain and maintain market share.
Preference for Newer Agents: Increasingly, healthcare providers and payers favor newer drug classes (GLP-1 RAs, SGLT2 inhibitors) due to their demonstrable benefits beyond glycemic control, such as cardiovascular and renal protection. This limits the market opportunity for older FDCs, especially in patients with comorbidities.
Payer Restrictions: Pharmacy benefit managers (PBMs) and national health systems may impose restrictions, step-therapy requirements, or prefer specific generic manufacturers based on cost and volume agreements, impacting market access for individual products.
Supply Chain Reliability: Ensuring a consistent and reliable supply chain for APIs and finished products is crucial, especially given the global nature of generic manufacturing and potential geopolitical or logistical disruptions.
Cost-Effectiveness Studies: Demonstrating cost-effectiveness against both monotherapies and newer combination therapies is vital for securing favorable formulary status and reimbursement, though the cost advantage of these older generics is significant.

What are the Key Trends and Future Outlook?

The future outlook for repaglinide and metformin hydrochloride FDCs is one of a maturing market facing sustained pressure from newer therapeutic agents and shifting treatment paradigms.

Key Market Trends:

Continued Generic Dominance and Price Decline: The market will remain dominated by generics, with ongoing price erosion as competition intensifies.
Declining Market Share in Developed Nations: In North America and Europe, the market share for these older FDCs is expected to continue to shrink as guidelines and clinical practice evolve to favor agents with broader benefits.
Sustained Volume in Emerging Markets: In regions with high T2DM prevalence and significant cost constraints, repaglinide and metformin hydrochloride FDCs will likely maintain a considerable volume share due to their affordability and established efficacy for glycemic control.
Focus on Combination Therapies: While newer combinations are gaining traction, cost-conscious healthcare systems may continue to rely on older, less expensive FDCs as part of a broader oral therapy strategy.
Therapeutic Inertia: Prescriber comfort and established treatment protocols may lead to continued, albeit diminishing, use in certain patient populations or healthcare settings.

Future Outlook:

Niche Market: Repaglinide and metformin hydrochloride FDCs will likely consolidate into a niche market segment primarily serving cost-sensitive regions or specific patient profiles where newer agents are less accessible or indicated.
Limited Innovation: Significant investment in innovation for this specific FDC is unlikely, with R&D efforts in T2DM focusing on novel mechanisms of action, combination therapies involving newer drug classes, and improved delivery systems.
Acquisition and Consolidation: Smaller generic players might be acquired by larger entities seeking to consolidate market share and leverage economies of scale in manufacturing and distribution.
Potential for Off-Label Use in Combination: While FDCs are standardized, the individual components may see continued use in various combination regimens dictated by clinical necessity and cost considerations.

Key Takeaways

The repaglinide and metformin hydrochloride FDC market is mature and characterized by extensive generic competition and significant price erosion.
Foundational patents have expired, leaving limited remaining intellectual property primarily in formulation and manufacturing processes.
The market is dominated by generic manufacturers, particularly from India and China, serving global markets with a strong emphasis on affordability.
Pricing is highly competitive and geographically variable, with ongoing downward pressure. Reimbursement is generally favorable for generics but increasingly challenged by newer antidiabetic agents with superior clinical outcome data.
Market access is hampered by the preference for newer drug classes (GLP-1 RAs, SGLT2 inhibitors) offering cardiovascular and renal benefits, leading to a projected modest decline or flat growth.
The future outlook points to a shrinking market share in developed nations, with sustained volume in cost-sensitive emerging markets, solidifying its position as a niche therapeutic option.

Frequently Asked Questions

What is the primary therapeutic benefit of the repaglinide and metformin hydrochloride combination?

The combination offers dual mechanisms of action to improve glycemic control in type 2 diabetes. Repaglinide stimulates insulin secretion from pancreatic beta cells, primarily lowering postprandial glucose, while metformin reduces hepatic glucose production and improves insulin sensitivity, lowering fasting and postprandial glucose.

Why has the market for this FDC experienced significant price erosion?

The primary driver of price erosion is the expiration of all key patents covering repaglinide, metformin, and their fixed-dose combination formulations. This has allowed numerous generic manufacturers to enter the market, leading to intense competition and subsequent price reductions.

How do repaglinide and metformin hydrochloride FDCs compare to newer antidiabetic drugs like SGLT2 inhibitors or GLP-1 receptor agonists?

Newer drug classes, such as SGLT2 inhibitors and GLP-1 receptor agonists, offer significant advantages beyond glycemic control, including proven benefits in reducing cardiovascular events, slowing kidney disease progression, and promoting weight loss. Repaglinide and metformin hydrochloride FDCs primarily focus on glycemic control and lack these broader metabolic benefits, making them less favored in current treatment guidelines for patients with comorbidities.

Are there any remaining patent protections that could impact generic competition?

While foundational patents have expired, some minor patent protections might still exist for specific advanced formulations, novel manufacturing processes, or unique polymorphic forms. However, these are unlikely to prevent broad generic entry or significantly alter the competitive landscape for standard FDC formulations.

What is the projected market trajectory for repaglinide and metformin hydrochloride FDCs in emerging economies versus developed nations?

In emerging economies, where cost remains a significant barrier to access and T2DM prevalence is high, repaglinide and metformin hydrochloride FDCs are expected to maintain substantial volume due to their affordability. In contrast, developed nations will likely see continued market share decline as newer, more beneficial therapies become standard of care, even with higher costs.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/

[2] European Medicines Agency. (n.d.). EudraGMDP. Retrieved from https://eudragmdp.ema.europa.eu/

[3] International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). Retrieved from https://www.diabetesatlas.org/

[4] U.S. Pharmacopeia. (n.d.). Generic Drug Resources. Retrieved from https://www.usp.org/

[5] Fierce Pharma. (Various Dates). Pharmaceutical industry news and analysis. Retrieved from https://www.fiercepharma.com/

[6] EvaluatePharma. (Various Dates). Pharmaceutical market intelligence and analytics. Retrieved from https://www.evaluate.com/

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	22
DailyMed Link:	REPAGLINIDE AND METFORMIN HYDROCHLORIDE at DailyMed

Sponsor	Phase
Novartis Pharmaceuticals	Phase 1
Medicines for Malaria Venture	Phase 1
AstraZeneca	Phase 2/Phase 3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin	REPAGLINIDE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; repaglinide	TABLET;ORAL	200624-001	Jul 15, 2015		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Lupin	REPAGLINIDE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; repaglinide	TABLET;ORAL	200624-002	Jul 15, 2015		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

REPAGLINIDE AND METFORMIN HYDROCHLORIDE Drug Patent Profile

When do Repaglinide And Metformin Hydrochloride patents expire, and when can generic versions of Repaglinide And Metformin Hydrochloride launch?

AI Deep Research

Questions you can ask:

Summary for REPAGLINIDE AND METFORMIN HYDROCHLORIDE

Recent Clinical Trials for REPAGLINIDE AND METFORMIN HYDROCHLORIDE

US Patents and Regulatory Information for REPAGLINIDE AND METFORMIN HYDROCHLORIDE

Repaglinide and Metformin Hydrochloride Market Dynamics and Financial Trajectory